Cara Therapeutics Inc. (CARA)
NASDAQ: CARA
· Real-Time Price · USD
5.32
-0.14 (-2.56%)
At close: Apr 15, 2025, 3:59 PM
Cara Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2024 |
|---|---|
| Commercial supply revenue Revenue | 640K |
| Commercial supply revenue Revenue Growth | n/a |
| Other revenue Revenue | 4.33M |
| Other revenue Revenue Growth | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 4.64M | 6.83M | 6.47M | 6.37M | 6.79M | 6.55M | 6.75M | 7.51M | 6.86M | 6.43M | 6.91M | 7.54M | 9.31M | 11.51M | 5.85M | 5.62M | 6.33M | 6.63M | 5.2M | 5.39M | 4.54M | 4.62M | 4.2M | 4.97M | 3.89M | 4.71M | 3.21M | 3.67M | 3.68M | 3M | 3.79M | 2.65M | 2.38M | 2.04M | 2.08M | 2.4M | 2.1M | 2.16M | 1.78M | 1.83M | 1.73M |
| Selling, General, and Administrative Revenue Growth | -32.13% | +5.50% | +1.66% | -6.15% | +3.62% | -3.05% | -10.10% | +9.50% | +6.75% | -7.00% | -8.30% | -19.08% | -19.08% | +96.75% | +4.11% | -11.27% | -4.44% | +27.58% | -3.60% | +18.78% | -1.73% | +9.82% | -15.45% | +27.95% | -17.51% | +46.94% | -12.52% | -0.33% | +22.77% | -20.87% | +42.67% | +11.42% | +16.83% | -2.07% | -13.47% | +14.52% | -2.82% | +21.68% | -3.11% | +5.77% | n/a |
| Research and Development Revenue | 319K | 171K | 1.36M | 9.31M | 21.95M | 28.37M | 25.45M | 30.31M | 24.33M | 26.01M | 24.69M | 19.91M | 21.27M | 22.83M | 15.51M | 25.23M | 19.13M | 27.14M | 21.07M | 26.11M | 33.54M | 29.86M | 35.99M | 24.36M | 23.61M | 22.8M | 22.3M | 17M | 13.43M | 11.58M | 9.15M | 6.96M | 20.84M | 20.28M | 9.67M | 10.76M | 8.55M | 7.57M | 5.58M | 4.68M | 3.38M |
| Research and Development Revenue Growth | +86.55% | -87.44% | -85.37% | -57.60% | -22.63% | +11.48% | -16.03% | +24.56% | -6.44% | +5.34% | +24.04% | -6.43% | -6.82% | +47.16% | -38.50% | +31.85% | -29.51% | +28.83% | -19.31% | -22.15% | +12.30% | -17.03% | +47.77% | +3.17% | +3.55% | +2.22% | +31.18% | +26.63% | +15.99% | +26.50% | +31.46% | -66.59% | +2.76% | +109.67% | -10.12% | +25.91% | +12.92% | +35.53% | +19.21% | +38.38% | n/a |